Join the CHARM2 Study for Early Cancer Detection

Written By BRCAinBC

The CHARM Consortium is recruiting participants for its new study, CHARM2: Evaluating the Performance of a cfDNA Blood Test for Early Cancer Detection.

The study is seeking individuals who:

  • Have a pathogenic variant in BRCA1, BRCA2, PALB2, CDH1, MLH1, MSH2, MSH6, PMS2, EPCAM, or TP53.

  • Are cancer-free for at least 3 years (with or without a prior cancer history).

The CHARM study is now open to BC patients, with sample collection starting in the New Year. If you have a pathogenic variant in BRCA1 or BRCA2, you can contact:

Sara Singh at
sara.singh@bccancer.bc.ca
604-649-7081

Learn more and see if you’re eligible here.

Read more here

BRCAinBC
Previous

Fight Against Pancreatic Cancer: Participate in the PRECEDE Study
Next

Pancreatic Cancer Risk: Management and Options for BRCA+ British Columbians